Physician profile
Christopher Buff
NPI 1417918012
$345.98
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $304 · 2020: $42.30.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $119.42 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.86 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $25.01 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $24.36 | 2019 | |
| Astellas Pharma US INC | $23.87 | 2019 | |
| Abbott Laboratories | $20.92 | 2019 | |
| Abbvie INC. | $19.40 | 2019 | |
| Novartis Pharmaceuticals Corporation | $17.89 | 2019 | |
| Amarin Pharma, INC. | $15.16 | 2020 | |
| Pfizer INC. | $14.55 | 2020 | |
| Mannkind Corporation | $12.54 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Buff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.